{"entity":{"id":"nct04280081","kind":"trial","name":"A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer a","aka":["LIBRETTO-321"],"tldr":"A phase 2 trial of Selpercatinib in thyroid cancer, run by Eli Lilly and Company, active and no longer recruiting.","summary":"A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation is a phase 2 interventional study registered as NCT04280081 by Eli Lilly and Company, with 77 participants enrolled, started 2020-03-16 and due to reach its primary completion in 2021-03-25. Interventions recorded: Selpercatinib. Conditions listed: Solid Tumor, Medullary Thyroid Cancer. Results were posted on ClinicalTrials.gov in 2022; the figures recorded here are the registry's, not a publication's.","status":"active","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT04280081","url":"https://clinicaltrials.gov/study/NCT04280081"}],"tags":["ctgov-ingest"],"related":[],"cancers":["thyroid","medullary-thyroid-cancer"],"sections":[],"technologies":["kinase-inhibitors"],"targets":[],"drugs":["selpercatinib"],"companies":["eli-lilly"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04280081","phase":"2","setting":"A Phase 2 Study of Oral Selpercatinib (LOXO-292) in Patients With Advanced Solid Tumors, Including Rearranged in Transfection (RET) Fusion-Positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation","sponsor":"Eli Lilly and Company","started":"2020-03-16","startedType":"actual","yearReported":2022,"enrolled":77,"enrolledBasis":"registry","outcomes":[{"endpoint":"Primary Analysis Set: Overall Response Rate (ORR): Percentage of Participants With Complete Response (CR) or Partial Response (PR) as Assessed by Independent Review Committee (IRC), Overall Response (CR/PR)","primary":true,"unit":"%","arms":[{"name":"RET Fusion Positive Non-small Cell Lung Cancer (NSCLC) Cohort 1","n":26,"value":69.2,"note":"95% CI 48.2 to 85.7; Figures from the ClinicalTrials.gov results section (first posted 2022-06-02), not from a publication"},{"name":"RET Fusion Positive Thyroid Cancer (TC) Cohort 1","n":1,"value":100,"note":"95% CI 2.5 to 100.0"},{"name":"RET Mutant Medullary Thyroid Cancer (MTC) Cohort 2","n":26,"value":57.7,"note":"95% CI 36.9 to 76.6"}],"source":"https://clinicaltrials.gov/study/NCT04280081?tab=results"},{"endpoint":"Enrolled Population: Overall Response Rate (ORR): Percentage of Participants With Complete Response (CR) or Partial Response (PR) as Assessed by IRC, Overall Response (CR/PR)","primary":true,"unit":"%","arms":[{"name":"Non-small Cell Lung Cancer (All NSCLC)","n":47,"value":66,"note":"95% CI 50.7 to 79.1; Figures from the ClinicalTrials.gov results section (first posted 2022-06-02), not from a publication"},{"name":"Thyroid Cancer (All TC)","n":1,"value":100,"note":"95% CI 2.5 to 100.0"},{"name":"Medullary Thyroid Cancer (All MTC)","n":29,"value":58.6,"note":"95% CI 38.9 to 76.5"}],"source":"https://clinicaltrials.gov/study/NCT04280081?tab=results"}]},"route":"/trials/nct04280081/","neighbours":{"cancer":[{"id":"medullary-thyroid-cancer","kind":"cancer","name":"Medullary thyroid cancer","route":"/cancers/medullary-thyroid-cancer/"},{"id":"thyroid","kind":"cancer","name":"Thyroid cancer","route":"/cancers/thyroid/"}],"technology":[{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"selpercatinib","kind":"drug","name":"Selpercatinib","route":"/drugs/selpercatinib/"}],"company":[{"id":"eli-lilly","kind":"company","name":"Eli Lilly (incl. Loxo)","route":"/companies/eli-lilly/"}]}}